• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center


    Functional genomics yields drivers, mutations, and pathways in leukemia

    The study of genes, mutations, and collective pathways contributing to leukemia is a cornerstone of the DF/HCC Leukemia Program, led by Thomas Look, MD (DFCI) and co-leaders David Scadden, MD (MGH), Pier Paolo Pandolfi, MD, PhD (BIDMC), and Scott Armstrong, MD, PhD (CHB)

    Twenty-four new members join DF/HCC

    Twenty-four individuals have recently joined DF/HCC

    BWH names Nabel next president
    Szostak wins Nobel Prize
    Fall eNews

    The Fall edition of eNews, DF/HCC's quarterly newsletter, has just been published

    Bench to bedside translational science doubling myeloma survival

    Ive been at this for 30 years and the last five years have been truly remarkable, says Kenneth Anderson, MD (DFCI)

    Abiraterone trial to launch in early stage prostate cancer

    A highly anticipated new androgen synthesis inhibitor, abiraterone acetate, will be the subject of the first clinical study in men with localized, but high-risk, prostate cancer

Displaying results 113 to 119 out of 229